Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Phenazopyridine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Symbio, LLC
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 26, 2012
Lead Product(s) : Phenazopyridine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Symbio, LLC
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Phenazopyridine
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Oxford Pharmaceutical Resources, Inc. | Sristek Clinical Research Solutions Limited | Biostudy Solutions, LLC
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluate the Safety and Efficacy of Phenazopyridine Hydrochloride Tablets, USP 200 mg vs. Placebo
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 08, 2010
Lead Product(s) : Phenazopyridine
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Oxford Pharmaceutical Resources, Inc. | Sristek Clinical Research Solutions Limited | Biostudy Solutions, LLC
Deal Size : Inapplicable
Deal Type : Inapplicable